Company: BIAF
Filing Date: 2025-11-07
Form Type: DEF 14A
Source: 0001493152-25-021269
Chunk: 5

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-07
Form: DEF 14A
Chunk 5
---
’s license. If you are a beneficial owner of Common Stock that is held of record by a bank, broker, or other nominee, you will also need proof of ownership to be admitted. In this regard, a recent brokerage statement or a letter from your bank or broker are examples of proof of ownership. The Company reserves the right to prohibit cameras, recording equipment, or electronic devices in the Special Meeting.

What am I voting on at the Special Meeting?

The purpose of the Special Meeting is to vote on the following items described in this Proxy Statement:

| Proposal No. 1:                                                                                                                           
 To consider and approve issuance of up to an aggregate of 271,500 shares of our Common Stock upon the exercise of (i) 223,831 shares      
 of our Common Stock issuable upon exercise of Common Stock purchase warrants issued in connection with our private placement offering     
 that closed on August 14, 2025 (the “August 2025 Common Warrants”), (ii) 47,669 shares of our Common Stock                                
 issuable upon exercise of Common Stock purchase warrants issued in connection with our warrant inducement transaction (the “Warrant       
 Inducement”) that closed on August 14, 2025 (the “August 2025 Inducement Warrants”), together                                             
 the August 2025 Common Warrants and the Inducement Warrants, the “August 2025 Warrants”), respectively,                                   
 that may be equal to or exceed 20% of our Common Stock outstanding before such offering (the “Warrant Exercise Proposal”).                |
| Proposal No. 2:                                                                                                                           
 To consider and approve an anti-dilution provision of the August 2025 Warrants and the reduction in the exercise price of the August      
 2025 Warrants (subject to a floor price of $4.50 per share) and corresponding increase in the number of shares issuable upon exercise     
 thereof up to an aggregate maximum of 365,620 shares of our Common Stock, resulting from the triggering of such anti-dilution provision   
 (the “Warrant Anti-Dilution Adjustment Proposal”).                                                                                        |
| Proposal No. 3:                                                                                                                           
 To consider and approve an anti-dilution provision of the Series B Preferred Stock and the reduction in the exercise price of             
 the Series B Preferred Stock (subject to a floor price of $3.00 per share) and corresponding increase in the number of shares of          
 Common Stock issuable upon conversion of the Series B Preferred Stock thereof